- $8.72bn
- $8.22bn
- $108.78m
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
ImmunoGen up on positive data from rare blood cancer drug trial
Brief: Immunogen Presents Updated Findings From Cadenza Trial Of Pivekimab Sunirine
U.S. STOCKS ON THE MOVE-Spotify, Akero Therapeutics, Cyxtera Technologies
U.S. STOCKS ON THE MOVE-Tesla, Moderna, Oil tanker firms
Cancer drugmakers rise as industry meet fuels investor interest (updated)
U.S. STOCKS ON THE MOVE-Foghorn Therapeutics, Novavax, Apple
Cancer drugmakers rise as industry meet fuels investor interest
Cancer drug developers up on presenting promising data from studies
U.S. STOCKS ON THE MOVE-Energy firms, ImmunoGen, CIRCOR
ImmunoGen surges as ovarian cancer therapy cuts disease progression risk in study
Brief: Immunogen Says ELAHERE Demonstrates 35% Reduction In Risk Of Disease Progression Or Death Versus Chemotherapy
Cerevel Therapeutics rises on new CFO appointment
Brief: Immunogen Announces Results From The Phase 3 Mirasol Trial Selected As Late-Breaking Presentation For Asco 2023 Annual Meeting
Brief: Immunogen Announces Pricing Of Upsized Public Offering Of Common Stock
Brief: Immunogen Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Ruth's Hospitality, Mirion Technologies, Qualcomm
Mersana rises after peer Immunogen's ovarian cancer drug shows positive results
ImmunoGen surges after cancer drug study hits a 'home run'